Type I Diabetes

Latest News

source: COUR Pharmaceuticals
Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes

February 6th 2025

COUR Pharmaceuticals is about begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.

Pixel-Shot-stock.adobe.com
Continuous Glucose Monitors Predict Type 1 Diabetes Complications

February 1st 2025

Mahmood-stock.adobe.com
New Type of Stem Cell Transplant Shows Promise in Type 1 Diabetes

January 15th 2025

Halyna-stock.adobe.com
Diabetes Association Updates Guidelines for Type 1 Diabetes

January 6th 2025

Grandbrothers-stock.adobe.com
FDA Issues Complete Response for Zynquista in Type 1 Diabetes

January 1st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.